{"id":"W2023205599","doi":"10.1111/epi.12643","title":"Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase <scp>III</scp> extension study 307","year":2014,"lang":"en","type":"article","venue":"Epilepsia","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Cilag; Johnson and Johnson; UCB Pharma; Sun Pharma; H. Lundbeck A/S; Eisai; Pfizer; Ministero della Salute; National Institutes of Health; Upsher-Smith; Innovation and Technology Fund; Vertex Pharmaceuticals; Medichem; Agenzia Italiana del Farmaco, Ministero della Salute; Sunovion; European Commission; Sanofi; University of Melbourne; GlaxoSmithKline; Health and Health Services Research Fund; Royal Melbourne Hospital Neuroscience Foundation","keywords":"Irritability; Perampanel; Discontinuation; Somnolence; Tolerability; Medicine; Epilepsy; Adverse effect; Convulsion; Anesthesia; Pediatrics; Internal medicine; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001105651,0.0004796516,0.001292815,0.0003019506,0.0001763019,0.00006443686,0.0001481762,0.0002432238,0.00005909939],"category_scores_gemma":[0.001407904,0.0003644474,0.0001311818,0.0002061423,0.0002802753,0.0001851307,0.0001819443,0.0005452124,0.00001392213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009080437,"about_ca_system_score_gemma":0.0001716575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001434747,"about_ca_topic_score_gemma":0.0007553922,"domain_scores_codex":[0.9961388,0.0006199186,0.001014539,0.0009568,0.000647022,0.000622959],"domain_scores_gemma":[0.9965652,0.00149308,0.0002887149,0.0009264282,0.0001634534,0.0005631464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005084219,0.004127802,0.964155,0.0001250412,0.0006170134,0.001516366,0.008345322,0.000008371237,0.002891301,0.00002853526,0.002646015,0.01045507],"study_design_scores_gemma":[0.04400319,0.003317135,0.9473984,0.0002188666,0.0002493889,0.00009578038,0.001040497,0.0004641544,0.001217711,0.00009165887,0.001740204,0.0001629669],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953613,0.00152735,0.00005566013,0.0004585001,0.0001360897,0.001517754,0.0005991938,0.00006974768,0.0002744433],"genre_scores_gemma":[0.9966272,0.0007565825,0.0004813265,0.0003311004,0.0001476854,0.000064375,0.0005979774,0.00005412797,0.0009396362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03891897,"threshold_uncertainty_score":0.9998807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02865429529973181,"score_gpt":0.3297866609927779,"score_spread":0.3011323656930461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}